Loss widens at Proximagen on R&D spend 'that should have been higher'
This article was originally published in Scrip
Executive Summary
Neuro-focused drug developer Proximagen reported widened losses in 2010 following a significant increase in R&D spending, which more than doubled to £6.1 million from £2.8 million the previous year. However, Proximagen had initially been prepared to spend much more on R&D during the yeat, CEO Kenneth Mulvany told Scrip.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.